Frank Spillmann

Frank Spillmann

Auto-generated profile, based on publicly available information

Frank Spillmann

Department of Cardiology and Pneumology, Charité, University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2008 in Circulation
Verified
Journal Article
Closed access
PDF file
DWDirk Westermann
Dirk Westermann
MKMario Kasner
Mario Kasner
PSPaul Steendijk
Paul Steendijk
FSFrank Spillmann
Frank Spillmann
ARAlexander Riad
Alexander Riad
CTCarsten TschöpE
Carsten TschöpE
Background— Increased left ventricular stiffness is a distinct finding in patients who have heart failure with normal ejection fraction (HFNEF). To elucidate how diastolic dysfunction contributes to heart failure symptomatology during exercise, we conducted a study using an invasive pressure-volume loop approach and measured cardiac function at rest and during atrial pacing and handgrip exercise. Methods and Results— Patients with HFNEF (n=70) and patients without heart failure symptoms (n=20) were enrolled. Pressure-volume loops were measured with a conductance catheter during basal conditions, handgrip exercise, and atrial pacing with 120 bpm to analyze diastolic and systolic left ventricular function. During transient preload reduction, the diastolic stiffness constant was measured directly. Diastolic function with increased stiffness was significantly impaired in patients with HFNEF during basal conditions. This was associated with increased end-diastolic pressures during handgrip exercise and with decreased stroke volume and a leftward shift of pressure-volume loops during atrial pacing. Conclusions— Increased left ventricular stiffness contributed to increased end-diastolic pressure during handgrip exercise and decreased stroke volume during atrial pacing in patients with HFNEF. These data suggest that left ventricular stiffness modulates cardiac function in HFNEF patients and suggests that diastolic dysfunction with increased stiffness is a target for treating HFNEF.

5 October 2007 in Basic Research in Cardiology
Verified
Journal Article
Closed access
PDF file
DWD. Westermann
D. Westermann
SLS. Linthout
S. Linthout
SDS. Dhayat
S. Dhayat
Nasser Abdalla DhayatNasser Abdalla Dhayat
Nasser Abdalla Dhayat
ASA. Schmidt
A. Schmidt
CTC. Tschöpe
C. Tschöpe

16 April 2010 in Circulation Research
Verified
Journal Article
Open access
PDF file
MMMarco Meloni
Marco Meloni
Andrea CaporaliAndrea Caporali
Andrea Caporali
GGGallia GRAIANI
Gallia GRAIANI
CLCostanza Lagrasta
Costanza Lagrasta
Rajesh KatareRajesh Katare
Rajesh Katare
Costanza EmanueliCostanza Emanueli
Costanza Emanueli
Rationale : Nerve growth factor (NGF) promotes angiogenesis and cardiomyocyte survival, which are both desirable for postinfarction myocardial healing. Nonetheless, the NGF potential for cardiac repair has never been investigated. Objective : To define expression and localization of NGF and its high-affinity receptor TrkA (tropomyosin-related receptor A) in the human infarcted heart and to investigate the cardiac roles of both endogenous and engineered NGF using a mouse model of myocardial infarction (MI). Methods and Results : Immunostaining for NGF and TrkA was performed on heart samples from humans deceased of MI or unrelated pathologies. To study the post-MI functions of endogenous NGF, a NGF-neutralizing antibody (Ab-NGF) or nonimmune IgG (control) was given to MI mice. To investigate the NGF therapeutic potential, human NGF gene or control (empty vector) was delivered to the murine periinfarct myocardium. Results indicate that NGF is present in the infarcted human heart. Both cardiomyocytes and endothelial cells (ECs) possess TrkA, which suggests NGF cardiovascular actions in humans. In MI mice, Ab-NGF abrogated native reparative angiogenesis, increased EC and cardiomyocyte apoptosis and worsened cardiac function. Conversely, NGF gene transfer ameliorated EC and cardiomyocyte survival, promoted neovascularization and improved myocardial blood flow and cardiac function. The prosurvival/proangiogenic Akt/Foxo pathway mediated the therapeutic benefits of NGF transfer. Moreover, NGF overexpression increased stem cell factor (the c-kit receptor ligand) expression, which translated in higher myocardial abundance of c-kit pos progenitor cells in NGF -engineered hearts. Conclusions : NGF elicits pleiotropic beneficial actions in the post-MI heart. NGF should be considered as a candidate for therapeutic cardiac regeneration.

1 July 2007 in Diabetes
Verified
Journal Article
Closed access
PDF file
DWDirk Westermann
Dirk Westermann
SLSophie Van Linthout
Sophie Van Linthout
SDSameer Dhayat
Sameer Dhayat
Nasser Abdalla DhayatNasser Abdalla Dhayat
Nasser Abdalla Dhayat
FEFelicitas Escher
Felicitas Escher
CTCarsten TschöpE
Carsten TschöpE
OBJECTIVE—We investigated the effect of pharmacological inhibition of the interleukin converting enzyme (ICE) on cardiac inflammation, apoptosis, fibrosis, and left ventricular function in an animal model of diabetes. RESEARCH DESIGN AND METHODS—Diabetes was induced in 24 Sprague-Dawley rats by injection of streptozotozin (STZ) (70 mg/kg). Diabetic animals were treated with the interleukin converting enzyme (ICE) inhibitor (ICEI) (n = 12) or with a placebo (n = 12). Nondiabetic rats served as controls (n = 12). Left ventricular function was documented 6 weeks after induction of diabetes. Cardiac tissue was analyzed for the expression of cytokines, intracellular adhesion molecule-1 and vascular cell adhesion molecule-1, leukocyte and macrophage integrins, and collagen. Phosphorylation of Akt was analyzed by Western blot and apoptosis by Blc-2 and Bax measurements. RESULTS—Left ventricular function was significantly impaired in diabetic animals. This was accompanied by a significant increase of cytokines, cell adhesion molecules, leukocytes and macrophages, and collagen content. In addition, the phosphorylation state of Akt was reduced. These changes were significantly attenuated in the diabetic group treated with ICEI. CONCLUSIONS—Cardiac dysfunction is associated with cardiac inflammation in experimental diabetic cardiomyopathy. Both of these—cardiac dysfunction and inflammation—are attenuated after treatment with ICEI. These data suggest that anticytokine-based therapies might be beneficial in diabetic cardiomyopathy.

23 June 2007 in Diabetologia
Verified
Journal Article
Closed access
PDF file
SLS. Van Linthout
S. Van Linthout
ARA. Riad
A. Riad
Nasser Abdalla DhayatNasser Abdalla Dhayat
Nasser Abdalla Dhayat
FSF. Spillmann
F. Spillmann
JDJ. Du
J. Du
CTC. Tschöpe
C. Tschöpe

1 August 2005 in Hypertension
Verified
Journal Article
Closed access
PDF file
GGGallia GRAIANI
Gallia GRAIANI
CLCostanza Lagrasta
Costanza Lagrasta
EMEnrica Migliaccio
Enrica Migliaccio
FSFrank Spillmann
Frank Spillmann
MMMarco Meloni
Marco Meloni
Costanza EmanueliCostanza Emanueli
Costanza Emanueli
Angiotensin II (Ang II), acting through its G protein–coupled AT 1 receptor (AT 1 ), contributes to the precocious heart senescence typical of patients with hypertension, atherosclerosis, and diabetes. AT 1 was suggested to transactivate an intracellular signaling controlled by growth factors and their tyrosin-kinase receptors. In cultured vascular smooth muscle cells, this downstream mechanism comprises the p66 Shc adaptor protein, previously recognized to play a role in vascular cell senescence and death. The aim of the present study was 2-fold: (1) to characterize the cardiovascular phenotype of p66 Shc knockout mice ( p66 Shc −/− ), and (2) to test the novel hypothesis that disrupting the p66 Shc might protect the heart from the damaging action of elevated Ang II levels. Compared with wild-type littermates ( p66 Shc +/+ ), p66 Shc −/− showed similar blood pressure, heart rate, and left ventricular wall thickness. However, cardiomyocyte number was increased in mutant animals, indicating a condition of myocardial hyperplasia. In p66 Shc +/+ , infusion of a sub-pressor dose of Ang II (300 nmol/kg body weight [BW] daily for 28 days) caused left ventricular hypertrophy and apoptotic death of cardiomyocytes and endothelial cells. In contrast, p66 Shc −/− were resistant to the proapoptotic/hypertrophic action of Ang II. Consistently, in vitro experiments showed that Ang II causes apoptotic death of cardiomyocytes isolated from p66 Shc +/+ hearts to a greater extent as compared with p66 Shc −/− cardiomyocytes. Our results indicate a fundamental role of p66 Shc in Ang II–mediated myocardial remodeling. In perspective, p66 Shc inhibition may be envisioned as a novel way to prevent the deleterious effects of Ang II on the heart.